Literature DB >> 10914921

Simple new method for effective concentration of 188Re solutions from alumina-based 188W-188Re generator.

S Guhlke1, A L Beets, K Oetjen, S Mirzadeh, H J Biersack, F F Knapp.   

Abstract

UNLABELLED: (188)Re is a useful generator-produced radioisotope currently under evaluation for a variety of therapeutic applications, including bone pain palliation and intravascular radiation therapy. Because the (188)W parent is available only in a relatively low specific activity (<0.15-0.19 GBq/mg) from reactor irradiation of enriched (186)W, relatively large volumes of 0.9% saline (>15 mL) are required for elution of the (188)Re daughter from traditional alumina-based (188)W-(188)Re generators. Because these large bolus volumes result in solutions with a relatively low specific volume activity of (188)Re (<1 GBq/mL for the 18.5-GBq generator), the availability of effective methods for eluent concentration is important. Our new approach is based on the use of 0.3 mol/L ammonium acetate as a representative salt of a weak acid instead of saline for generator elution.
METHODS: After generator elution, the ammonium acetate generator eluent (15-20 mL) is passed through a tandem IC-H Plus cation (Dowex-H)-anion (QMA Light) column system. Exchange of ammonium cations with hydrogen ions on the cation column forms an acetic acid solution containing perrhenate anions from which the macroscopic levels of the acetate anion of the eluent have been effectively removed. Because perrhenic acid is fully dissociated at this pH, the QMA Light column specifically traps the (188)Re-perrhenate, which is subsequently eluted with a low volume (<1 mL) of saline. Concentration ratios greater than 20:1 are readily achieved with this method.
RESULTS: A typical clinical-scale generator loaded with 19.2 GBq (188)W was used to validate the approach. Saline elution provided (188)Re in a 75%-80% yield. Although elution with 0.15 mol/L NH4OAc gave lower yields (55%-60%), use of 0.3 mol/L NH4OAc provided yields comparable with those of saline (70%-75%). (188)W parent breakthrough was not detected after passage of the bolus through the tandem concentration system. Bolus volumes of 15-20 mL, which initially contained as much as 11.1-14.8 GBq (188)Re, were readily concentrated to less than 1 mL saline using QMA Light cartridges. The generator was evaluated for more than 3 mo with no decrease in performance.
CONCLUSION: This approach represents a simple, rapid, and effective method using inexpensive disposable components of concentrating solutions of (188)Re for preparation of therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10914921

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  9 in total

1.  188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.

Authors:  Amal A El-Mabhouh; John R Mercer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-12       Impact factor: 9.236

2.  Binding of ReO4(-) with an engineered MoO4(2-)-binding protein: towards a new approach in radiopharmaceutical applications.

Authors:  Baikuntha P Aryal; Pedro Brugarolas; Chuan He
Journal:  J Biol Inorg Chem       Date:  2011-08-23       Impact factor: 3.358

3.  May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate.

Authors:  Amir Sabet; Feras Khalaf; Soha Mahjoob; Abdullah Al-Zreiqat; Hans-Jürgen Biersack; Samer Ezziddin
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-12-15

4.  (188)Re-HDD/lipiodol therapy for hepatocellular carcinoma: an activity escalation study.

Authors:  Bieke Lambert; Klaus Bacher; Luc Defreyne; Hans Van Vlierberghe; Jae Min Jeong; Rong Fu Wang; Jan van Meerbeeck; Peter Smeets; Roberto Troisi; Hubert Thierens; Filip De Vos; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12-07       Impact factor: 9.236

5.  The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts.

Authors:  Carol A Nelson; Michael T Azure; Christopher T Adams; Kurt R Zinn
Journal:  J Nucl Med       Date:  2014-10-30       Impact factor: 10.057

6.  Pharmacokinetics of radioimmunotherapeutic agent of direct labeling mAb 188Re-HAb18.

Authors:  Chao Lou; Zhi-Nan Chen; Hui-Jie Bian; Jie Li; Shou-Bo Zhou
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

7.  The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.

Authors:  Knut Liepe; Roswitha Runge; Jörg Kotzerke
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-22       Impact factor: 4.553

Review 8.  Radiolabeled Dendrimers for Nuclear Medicine Applications.

Authors:  Lingzhou Zhao; Meilin Zhu; Yujie Li; Yan Xing; Jinhua Zhao
Journal:  Molecules       Date:  2017-08-25       Impact factor: 4.411

9.  Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases.

Authors:  K Liepe; J Kropp; R Runge; J Kotzerke
Journal:  Br J Cancer       Date:  2003-08-18       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.